Skip to main content

Table 2 Basic characteristics of patients in the derivation set

From: Development and validation of a clinical prediction model for detecting coronary heart disease in middle-aged and elderly people: a diagnostic study

Indicators

CHD (n = 433)

Non-CHD (n = 155)

Statistics

P values

Demographics

 Male, N (%)

203 (46.88)

75 (48.39)

0.104a

0.747

 Age, years

64 (58, 69)

60 (55, 67)

3.533b

 < 0.001

 BMI, kg/m2

25.67 (24.03, 27.55)

26.04 (24.09, 29.07)

− 1.938b

0.053

Past medical history

 Smoking, N (%)

122 (28.18)

37 (23.87)

1.072a

0.300

 Diabetes, N (%)

203 (46.88)

47 (30.32)

12.807a

 < 0.001

 Hypertension, N (%)

261 (60.28)

96 (61.94)

0.132a

0.717

 Heart failure NYHA I-II, N (%)

18 (4.16)

7 (4.52)

0.036a

0.849

 Atrial fibrillation, N (%)

15 (3.46)

7 (4.52)

0.351a

0.554

Prior medication use

 Anti-platelet, N (%)

353 (81.52)

134 (86.45)

1.948a

0.163

 Statins, N (%)

343 (79.21)

128 (82.58)

0.811a

0.368

 ACEI/ARB, N (%)

246 (56.81)

83 (53.55)

0.494a

0.482

 Beta-blockers, N (%)

339 (78.29)

118 (76.13)

0.308a

0.579

 CCB, N (%)

237 (54.73)

72 (46.45)

3.140a

0.076

 Nitrates, N (%)

201 (46.42)

64 (41.29)

1.213a

0.271

Laboratory values

 ALT, IU/L

20 (15, 28)

20 (14, 28.5)

− 0.332b

0.740

 AST, IU/L

19 (16, 24)

20 (15.5, 23)

− 0.576b

0.565

 Scr, μmol/L

69.3 (58.3, 81.05)

67.3 (59.3, 78.5)

0.969b

0.333

Hs-CRP, mg/L

1.32 (0.65, 3.33)

1.48 (0.62, 2.57)

0.762b

0.446

TC, mmol/L

3.87 (3.22, 4.63)

4.33 (3.48, 4.88)

− 3.192b

0.001

TG, mmol/L

1.34 (1.06, 1.8)

1.43 (1.03, 1.88)

− 0.103b

0. 918

LDL-C, mmol/L

2.34 (1.88, 2.93)

2.53 (2.08, 3.12)

− 3.082b

0.002

HDL-C, mmol/L

1.09 (0.96, 1.27)

1.15 (1, 1.34)

− 1.748b

0.080

HCY, μmol/L

13.49 (11.26, 16.2)

13.27 (11.24, 15.03)

1.287b

0.198

HbA1c, %

6.2 (5.7, 7.2)

5.8 (5.5, 6.2)

5.053b

 < 0.001

NT-proBNP, pg/mL

91.5 (47.5, 176.5)

78 (40, 134)

1.844b

0.065

Arterial stiffness indices

 baPWV, m/s

17.81 (15.69, 20.02)

16.38 (13.89, 19.05)

4.641b

 < 0.001

 ABI

1.12 (1.02, 1.21)

1.15 (1.08, 1.22)

− 2.445b

0.014

Vascular endothelial function test

 FMD, %

7.6 (6.8, 9)

8 (7.2, 9.1)

− 2.181b

0.029

Echocardiographic values

 LAD, mm

37 (34, 40)

36 (34, 40)

1.085b

0.278

 LVEF, %

68 (63, 71)

68 (64, 72)

-1.220b

0.223

 LVMI, g/m2

88.25 (76.3, 102.26)

85.18 (71.75, 99.79)

1.386b

0.166

  1. Data were expressed as means ± standard deviations or as medians with interquartile ranges or as frequencies and percentages
  2. CHD coronary atherosclerotic heart disease, BMI body mass index, ACEI angiotensin converting enzyme inhibitor, ARB angiotensin receptor blocker, CCB calcium channel blockers, ALT alanine aminotransferase, AST aspartate aminotransferase, Scr serum creatinine, Hs-CRP hypersensitive C-reactive protein, TC total cholesterol, TG triglyceride, LDL-C low-density lipoprotein cholesterol, HDL-C high-density lipoprotein cholesterol, HCY homocysteine, HbA1c hemoglobin A1c; NT-proBNP N-terminal pro-B-type natriuretic peptide, baPWV brachial-ankle pulse wave velocity, ABI ankle-brachial index, FMD brachial artery flow-mediated vasodilatation, LAD eft atrium diameter, LVEF left ventricular ejection fraction, LVMI left ventricular mass index
  3. aχ2 value
  4. bZ value
Back to article page

European Journal of Medical Research

ISSN: 2047-783X

Contact us